Home > Back to Publisher > Report Information

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

BioSeeker Group AB
August 25, 2009
767 Pages - SKU: BIOS2427575

Abstract Table of Contents Related Reports

This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
Assisting you to make informed decisions in selecting lung cancer sub-indications that are known to be appropriate for your drug's properties
Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary

4 Table of Contents

2 About Cancer Highlights

3 Methodologies
4.1 List of Figures

4.2 List of Tables

5 Introduction

5.1 The Scope of this Report

5.2 Definitions

5.3 Abbreviations

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment

6.1 Drug Repositioning in Oncology

6.2 Introduction to Lung Cancer Drug Targets

6.2.1 Carboxy-lyase Activity Targets

6.2.2 Catalytic ActivityTargets

6.2.3 Cell Adhesion Molecule Activity Targets

6.2.4 Chaperone ActivityTargets

6.2.5 Chemokine Activity Targets

6.2.6 Complement Activity Targets

6.2.7 Cysteine-Type Peptidase Activity Targets

6.2.8 Cytokine Activity Targets

6.2.9 DNA Binding Targets

6.2.10 DNA Repair Protein Targets

6.2.11 DNA Topoisomerase Activity Targets

6.2.12 DNA-Directed DNA Polymerase Activity Targets

6.2.13 DNA-methyltransferase Activity Targets

6.2.14 Extracellular Ligand-Gated Ion Channel Activity Targets

6.2.15 Extracellular Matrix Structural Constituent Targets

6.2.16 G-protein Coupled Receptor Activity Targets

6.2.17 Glutathione Transferase Activity Targets

6.2.18 Growth Factor Activity Targets

6.2.19 GTPase Activity Targets

6.2.20 Hormone activity Targets

6.2.21 Hydrolase Activity Targets

6.2.22 Ion channel Activity Targets

6.2.23 Kinase Activity Targets

6.2.24 Kinase regulator activity Targets

6.2.25 Ligase Activity Targets

6.2.26 Lipase Activity Targets

6.2.27 Lipid Kinase Activity Targets

6.2.28 Metallopeptidase Activity Targets

6.2.29 Molecular Function Unknown Targets

6.2.30 Motor Activity Targets

6.2.31 Oxidoreductase Activity Targets

6.2.32 Peptidase Activity Targets

6.2.33 Peroxidase Activity Targets

6.2.34 Phosphoric Diester Hydrolase Activity Targets

6.2.35 Protein binding Targets

6.2.36 Protein Serine/Threonine Kinase Activity Targets

6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets

6.2.38 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets

6.2.39 Protein-Tyrosine Kinase Activity Targets

6.2.40 Receptor Activity Targets

6.2.41 Receptor binding Targets

6.2.42 Receptor Signaling Complex Scaffold Activity Targets

6.2.43 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets

6.2.44 RNA Binding Targets

6.2.45 RNA-Directed DNA Polymerase Activity Targets

6.2.46 Serine-Type Peptidase Activity Targets

6.2.47 Structural Constituent of Cytoskeleton Targets

6.2.48 Transcription Factor Activity Targets

6.2.49 Transcription Regulator Activity Targets

6.2.50 Transcription Regulator Activity Targets

6.2.51 Transferase Activity Targets

6.2.52 Transmembrane Receptor Activity Targets

6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

6.2.54 Transporter Activity Targets

6.2.55 Ubiquitin-Specific Protease Activity Targets

6.2.56 Other Targets

6.3 The Cancer Genome Project and Lung Cancer Targets

6.3.1 Lung Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

6.4 Structure-based Drug Design in Lung Cancer is Stimulated by Available Structure Data on Biological Targets

6.5 Target-Target Interactions among Identified Lung Cancer Targets

6.6 The Drug-Target Interactome

6.7 Protein Expression Levels of Identified Drug Targets of Lung Cancer Drugs

6.8 Pathway Analysis of Lung Cancer Drug Targets

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline?

7.1 Terminated Drug Target Profiles in Lung Cancer

7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lung Cancer Pipeline

7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline

7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lung Cancer Pipeline

7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline

7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline

7.7 Development Profiles of All Lung Cancer Drug Target Profiles

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound

8.1 Small Molecules

8.1.1 Background

8.1.2 Targets in Lung Cancer

8.2 Peptide/Protein Drugs

8.2.1 Background

8.2.2 Targets in Lung Cancer

8.3 Antibodies and Antibody-like Structures

8.3.1 Background

8.3.2 Targets in Lung Cancer

8.4 Nucleic Acid Therapies

8.4.1 Background

8.4.2 Targets in Lung Cancer

8.5 Gene Therapy

8.5.1 Background

8.5.2 Targets in Lung Cancer

8.6 Drug Delivery and Nanotechnology

8.6.1 Background

8.6.2 Targets in Lung Cancer

8.7 The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer

8.8 Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets

9 Selecting a Sub-Indication of Lung Cancer for Drug Development

9.1 Lung Cancer (general)

9.1.1 Players and their Compared Pipeline

9.1.2 Where is the Real Competition?

9.1.3 How Successful are They in Their Targeting Strategy?

9.2 Non-Small Cell Lung Cancer

9.2.1 Players and their Compared Pipeline

9.2.2 Where is the Real Competition?

9.2.3 How Successful are They in Their Targeting Strategy?

9.3 Small Cell Lung Cancer

9.3.1 Players and their Compared Pipeline

9.3.2 Where is the Real Competition?

9.3.3 How Successful are They in Their Targeting Strategy?

10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator

10.1 Abbott

10.2 Abraxis BioScience

10.3 Active Biotech

10.4 Adherex

10.5 Advantagene

10.6 AEgera

10.7 Aeterna Zentaris

10.8 Agennix

10.9 Aida Pharmaceuticals

10.10 Alchemia

10.11 Alethia Biotherapeutics

10.12 Allos Therapeutics

10.13 Amgen

10.14 Antisense Pharma

10.15 Antisoma

10.16 Anza Therapeutics

10.17 ApopLogic Pharmaceuticals

10.18 Archer Biosciences

10.19 Ariad

10.20 ArQule

10.21 Array BioPharma

10.22 Ascenta Therapeutics

10.23 Astellas

10.24 AstraZeneca

10.25 Bayer

10.26 Biogen Idec

10.27 Biokine Therapeutics

10.28 BioNumerik

10.29 Boehringer Ingelheim

10.30 Bristol-Myers Squibb

10.31 BTG

10.32 CanBas

10.33 Celator Pharmaceuticals

10.34 Cell Genesys

10.35 Cell Therapeutics

10.36 Celtic Pharma

10.37 Center of Molecular Immunology

10.38 Cephalon

10.39 CG Therapeutics

10.40 Chemokine Therapeutics

10.41 Chong Kun Dang

10.42 Clavis Pharma

10.43 CLL Pharma

10.44 Critical Outcome Technologies

10.45 Cyclacel

10.46 CytImmune Sciences

10.47 Cytokinetics

10.48 Dabur Pharma

10.49 Daiichi Sankyo

10.50 Dainippon Sumitomo Pharma

10.51 Dara Biosciences

10.52 Dendreon

10.53 Dong-A

10.54 Eisai

10.55 Eli Lilly

10.56 Endocyte

10.57 EntreMed

10.58 EpiCept

10.59 Exelixis

10.60 Galapagos

10.61 Gemin X Pharmaceuticals

10.62 Genentech

10.63 Genmab

10.64 Genta

10.65 GenVec

10.66 Genzyme

10.67 Geron

10.68 GlaxoSmithKline

10.69 GlobeImmune

10.70 GlycoGenesys

10.71 Hana Biosciences

10.72 Hoffmann-La Roche

10.73 Human Genome Sciences

10.74 Idera Pharmaceuticals

10.75 ImClone Systems

10.76 ImmunoCellular Therapeutics

10.77 Immunocore

10.78 ImmunoGen

10.79 Immunomedics

10.80 Incyte Corporation

10.81 Infinity Pharmaceuticals

10.82 Innovive

10.83 Inovio

10.84 Introgen Therapeutics

10.85 Ipsen

10.86 Isis Pharmaceuticals

10.87 Jennerex Biotherapeutics

10.88 Johnson & Johnson

10.89 Kiadis

10.90 Kyowa Hakko Kirin

10.91 Lorus Therapeutics

10.92 MacroGenics

10.93 Medarex

10.94 MediGene

10.95 Medisyn Technologies

10.96 Menarini

10.97 Merck KGaA

10.98 MethylGene

10.99 Micromet

10.100 Mirna Therapeutics

10.101 MolMed

10.102 Mologen

10.103 Nektar Therapeutics

10.104 NeoPharm

10.105 Nerviano Medical Sciences

10.106 Novacea

10.107 Novartis

10.108 OncoGenex Pharmaceuticals

10.109 Oncothyreon

10.110 OSI Pharmaceuticals

10.111 OXiGENE

10.112 PanaGin

10.113 PBL Therapeutics

10.114 PDL BioPharma

10.115 Pfizer

10.116 Pharmacyclics

10.117 PharmaGap

10.118 PharmaMar

10.119 Pharmexa

10.120 Pierre Fabre

10.121 Pro-Pharmaceuticals

10.122 Progen

10.123 Protox Therapeutics

10.124 Receptor BioLogix

10.125 Regulon

10.126 RESprotect

10.127 Samyang

10.128 Sanofi-Aventis

10.129 Sareum

10.130 Schering-Plough

10.131 Seattle Genetics

10.132 ShimodaAtlantic Oncology

10.133 Shire

10.134 Sigma-Tau

10.135 Simcere Pharmaceuticals

10.136 SRI International

10.137 SuperGen

10.138 Supratek Pharma

10.139 Switch Pharma

10.140 Taiho

10.141 Takeda

10.142 Taxolog

10.143 Tekmira Pharmaceuticals

10.144 Telik

10.145 Thallion Pharmaceuticals

10.146 Therion Biologics

10.147 Titan Pharmaceuticals

10.148 Tracon Pharmaceuticals

10.149 Tragara Pharmaceuticals

10.150 Transgene

10.151 Trion Pharma

10.152 Twinstrand Therapeutics

10.153 UCB

10.154 Valeant

10.155 Vaxon Biotech

10.156 Vertex Pharmaceuticals

10.157 Vion Pharmaceuticals

10.158 ViRexx

10.159 Voyager Pharmaceutical

10.160 Wilex

10.161 Wyeth

10.162 Xerion

10.163 Xoma

10.164 Yakult Honsha

10.165 YM BioSciences

10.166 Zivena

10.167 Non-industrial Organizations

11 Disclaimer

13 Company Index

4.1 List of Figures

12 Drug Index
Figure 1: Overall Breakdown of the Included Lung Cancer Therapeutic Pipeline by Sub-Indication and Stage of Development

Figure 2: Visualization of Target-Target Interactions Among Lung Cancer Drug Targets

Figure 3: The Drug-Protein Interactome of Lung Cancer Drugs -Clusters I

Figure 4: The Drug-Protein Interactome of Lung Cancer Drugs - Clusters II

Figure 5: Head-to-Head Targeting Interactome of Lung Cancer Drugs

Figure 6: Distribution of Compound Types among Lung Cancer Drugs

Figure 7: Primary Sub-cellular Localization of Drug Targets

Figure 8: Breakdown of the Lung Cancer (general) Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development

Figure 9: Compound Strategy Breakdown of the Lung Cancer (general) Pipeline

Figure 10: Breakdown of the Non-Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development

Figure 11: Compound Strategy Breakdown of the Non-Small Cell Lung Cancer Pipeline

Figure 12: Breakdown of the Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development

Figure 13: Compound Strategy Breakdown of the Small Cell Lung Cancer Pipeline

4.2 List of Tables

Table 1: Competitive Pressure Force Among Lung Cancer Drugs

Table 2: Overview of Drug Target Profile Themes

Table 3: Terminally Ceased Therapeutic Lung Cancer Targets

Table 4: Drug Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census

Table 5: Identity of Lung Cancer Drug Targets with Available Biological Structures

Table 6: Number of Target-Target Interactions among Lung Cancer Drug Targets

Table 7: Drug-Protein Interactome Clusters

Table 8: Lung Cancer Drug Targets with Available Protein Expression Profiles

Table 9: Expression Levels of Identified Drug Targets in Lung Cancer Tissue

Table 10: Pathway Summary

Table 11: Drug Targets without any Identified Assigned Pathways

Table 12: Pathway Profile According to BioCarta of Lung Cancer Drug Targets

Table 13: Pathway Profile According to KEGG of Lung Cancer Drug Targets

Table 14: Pathway Profile According to NetPath of Lung Cancer Drug Targets

Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness

Table 16: Top Competitive Lung Cancer Target Profiles

Table 17: Terminated Drug Target Strategies in Lung Cancer

Table 18 New and Unique Lung Cancer Target Strategies in Pre-Registration to Marketed

Table 19: New and Unique Lung Cancer Target Strategies in Phase III Clinical Development

Table 20: New and Unique Lung Cancer Target Strategies in Phase II Clinical Development

Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs .. 336

Table 22 New and Unique Lung Cancer Target Strategies in Phase I Clinical Development

Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs

Table 24: New and Unique Lung Cancer Target Strategies in Preclinical Development

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs

Table 26: The Progression, Maturity and Competitive Comparison of Lung Cancer Drug Target Profiles in

Development

Table 27: Overview of Compound Strategy Competition in Lung Cancer

Table 28:Overview of the Competitive Landscape of Small Molecular Drugs in Lung Cancer

Table 29: Head-to-Head Target Competition Between Small Molecule Drugs for the Treatment of Lung Cancer

Table 30: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lung

Cancer

Table 31: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Lung

Cancer Drugs in Development

Table 32: Overview of the Competitive Landscape of Peptide Based Drugs in Lung Cancer

Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Lung

Cancer Drug in Development

Table 34:Overview of the Competitive Landscape of Protein Based Drugs in Lung Cancer

Table 35: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lung

Cancer

Table 36: The Progression, Maturity and Competitive Comparison of Protein Based Lung Cancer Drug Target

Profiles in Development

Table 37:Overview of the Competitive Landscape of Antibody Drugs in Lung Cancer

Table 38: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lung Cancer

Table 39: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Lung Cancer Drugs in Development

Table 40:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lung Cancer

Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Lung Cancer Drugs in Development

Table 42: Vectors in Gene Therapy

Table 43:Overview of the Competitive Landscape of Gene Therapy Drugs in Lung Cancer

Table 44: The Competition Through Close Mechanistic Approximation Between Gene Therapy Drugs in Lung Cancer

Table 45: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Lung Cancer Drugs in Development

Table 46:Overview of the Competitive Landscape of Reformulated Drugs in Lung Cancer

Table 47: The Competition Through Close Mechanistic Approximation Between Reformulated Drugs in Lung Cancer

Table 48: The Progression, Maturity and Competitive Comparison of Target Profiles of Reformulated Lung Cancer Drugs in Development

Table 49: The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer

Table 50: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets

Table 51: Competitive Summary of Lung Cancer Drugs by Sub-Indication

Table 52: Players in the Field of Lung Cancer (general) Drug Development and their Compared Pipeline

Table 53: The Competition Through Close Mechanistic Approximation Between Lung Cancer (general) Drugs

Table 54: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lung Cancer

(general) Drug Development

Table 55: Players in the Field of Non-Small Cell Lung Cancer Drug Development and their Compared Pipeline 430

Table 56: The Competition Through Close Mechanistic Approximation Between Non-Small Cell Lung Cancer

Drugs

Table 57: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Small Cell Lung Cancer Drug Development

Table 58: Players in the Field of Small Cell Lung Cancer Drug Development and their Compared Pipeline

Table 59: The Competition Through Close Mechanistic Approximation Between Small Cell Lung Cancer Drugs

Table 60: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Small Cell Lung

Cancer Drug Development

Table 61: Abbott's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 62: Abraxis BioScience's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 63: Active Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 64: Adherex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 65: Advantagene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 66: AEgera's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 67: Aeterna Zentaris’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 68: Agennix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 69: Aida Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 70: Alchemia's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 71: Alethia Biotherapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 72: Allos Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 73: Amgen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 74: Antisense Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 75: Antisoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 76: Anza Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 77: ApopLogic Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 488

Table 78: Archer Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 79: Ariad's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 80: ArQule's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 81: Array BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 82: Ascenta Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 83: Astellas’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 84: AstraZeneca's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 85: Bayer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 86: Biogen Idec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 87: Biokine Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 88: BioNumerik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 89: Boehringer Ingelheim's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 90: Bristol-Myers Squibb's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 91: BTG's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 92: CanBas’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 93: Celator Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 94: Cell Genesys’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 95: Cell Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 96: Celtic Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 97: Center of Molecular Immunology's Included Lung Cancer Pipeline Composition and Competitive Fall-

Out

Table 98: Cephalon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 99: CG Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 100: Chemokine Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 101: Chong Kun Dang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 102: Clavis Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 103: CLL Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 104: Critical Outcome Technologies’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 105: Cyclacel's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 106: CytImmune Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 107: Cytokinetics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 108: Dabur Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 109: Daiichi Sankyo's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 110: Dainippon Sumitomo Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 111: Dara Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 112: Dendreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 113: Dong-A's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 114: Eisai's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table of Contents 4

Table 115: Eli Lilly's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 116: Endocyte's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 117: EntreMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 118: EpiCept's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 119: Exelixis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 120: Galapagos’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 121: Gemin X Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out.. 569

Table 122: Genentech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 123: Genmab's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 124: Genta's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 125: GenVec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 126: Genzyme's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 127: Geron's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 128: GlaxoSmithKline's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 129: GlobeImmune's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 130: GlycoGenesys’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 131: Hana Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 132: Hoffmann-La Roche's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 133: Human Genome Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 588

Table 134: Idera Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 135: ImClone Systems’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 136: ImmunoCellular Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 137: Immunocore's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 138: ImmunoGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 139: Immunomedics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 140: Incyte Corporation's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 141: Infinity Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 142: Innovive's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 143: Inovio's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 144: Introgen Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 145: Ipsen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 146: Isis Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 147: Jennerex Biotherapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 611

Table 148: Johnson & Johnson's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 149: Kiadis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 150: Kyowa Hakko Kirin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

4 Competitive Outlook on Lung Cancer Drug Development - The Missing

Handbook to New Product Planning And Portfolio Planning

Table 151: Lorus Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 152: MacroGenics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 153: Medarex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 154: MediGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 155: Medisyn Technologies’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 156: Menarini's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 157: Merck KGaA's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 158: MethylGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 159: Micromet's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 160: Mirna Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 161: MolMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 162: Mologen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 163: Nektar Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 164: NeoPharm's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 165: Nerviano Medical Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out 644

Table 166: Novacea's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 167: Novartis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 168: OncoGenex Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 169: Oncothyreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 170: OSI Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 171: OXiGENE's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 172: PanaGin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 173: PBL Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 174: PDL BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 175: Pfizer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 176: Pharmacyclics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 177: PharmaGap's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 178: PharmaMar's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 179: Pharmexa's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 180: Pierre Fabre's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 181: Pro-Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 182: Progen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 183: Protox Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 184: Receptor BioLogix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 185: Regulon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 186: RESprotect's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table of Contents 4

Table 187: Samyang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 188: Sanofi-Aventis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 189: Sareum's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 190: Schering-Plough's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 191: Seattle Genetics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 192: ShimodaAtlantic Oncology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 193: Shire's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 194: Sigma-Tau's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 195: Simcere Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 698

Table 196: SRI International's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 197: SuperGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 198: Supratek Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 199: Switch Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 200: Taiho's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 201: Takeda's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 202: Taxolog's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 203: Tekmira Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 714

Table 204: Telik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 205: Thallion Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 717

Table 206: Therion Biologics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 207: Titan Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 208: Tracon Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 209: Tragara Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 723

Table 210: Transgene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 211: Trion Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 212: Twinstrand Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 213: UCB's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 214: Valeant's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 215: Vaxon Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 216: Vertex Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 217: Vion Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 218: ViRexx's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 219: Voyager Pharmaceutical's Included Lung Cancer Pipeline Composition and Competitive Fall-Out .. 736

Table 220: Wilex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 221: Wyeth's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 222: Xerion's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 223: Xoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 224: Yakult Honsha's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 225: YM BioSciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 226: Zivena's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Table 227: Non-industrial source's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service